A previous study from this group showed that the receptor for HCA2 is overexpressed in the retina following diabetes and its activation with the systemically administered compound BHB can reduce the NLRP3 inflammasome activity and reduce retinal damage [9]. This evidence concerns the gene NLRP3 and diabetes mellitus.